# Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

> **NCT01596400** · PHASE1 · COMPLETED · sponsor: **Kyowa Kirin Pharmaceutical Development Ltd** · enrollment: 19 (actual)

## Conditions studied

- Chemotherapy Induced Nausea and Vomiting

## Interventions

- **DRUG:** granisetron transdermal system
- **DRUG:** Granisetron IV

## Key facts

- **NCT ID:** NCT01596400
- **Lead sponsor:** Kyowa Kirin Pharmaceutical Development Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-08
- **Final completion:** 2016-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01596400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01596400, "Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01596400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*